
Benjamin Solomon, MBBS, PhD, FRACP, presents key data from the ALINA study investigating alectinib versus chemotherapy as adjuvant therapy in patients with stage IB–IIIA anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC).

Your AI-Trained Oncology Knowledge Connection!


Benjamin Solomon, MBBS, PhD, FRACP, presents key data from the ALINA study investigating alectinib versus chemotherapy as adjuvant therapy in patients with stage IB–IIIA anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC).

Benjamin Solomon, MBBS, PhD, FRACP, discusses interim findings from the phase 3 CROWN study in ALK-positive non–small cell lung cancer.

Published: September 20th 2020 | Updated:

Published: November 17th 2023 | Updated: